股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,00 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 有關須予披露交易 收購資產之 補充公佈 謹 此 提 述 李 氏 大 藥 廠 控 股 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 十 二 月 九 日 的 公 佈，內 容 有 關 收 購 所 購 資 產（「該公佈」）。除 另 有 界 定 者 外，本 公 佈 所 用 的 專 有 詞 彙 與 該 公 佈 所 用 者 具 有 相 同 涵 義。 本 公 司 謹 此 提 供 以 下 進 一 步 資 料： 有關所購資產的資料 下文載列截至二零二三年十二月三十一日及二零二四年十二月三十一日止年 度 所 購 資 產 應 佔 收 益 及 毛 利，乃 摘 錄 自 賣 方 的 經 審 核 財 務 報 ...

Michele Dalla Libera在公司的成长与发展过程中发挥了关键作用，尤其是在公司于2002年上市后的数年 间。他与创始人紧密合作，引领公司度过初创阶段。他主导了从义大利及其他欧洲国家引进药品的工 作，为公司建立了核心产品组合，奠定了坚实的基础，使公司从一家小型生物制药企业成长为拥有稳固 收入基础的更强大企业。 格隆汇12月18日丨李氏大药厂(00950.HK)痛宣布，公司业务发展高级总监Michele Dalla Libera先生已于 2025年12月15日逝世。 ...

智通财经APP讯，李氏大药厂(00950)发布公告，本公司业务发展高级总监Michele Dalla Libera先生 (Michele先生)已于2025年12月15日逝世。 ...

李氏大药厂(00950)发布公告，本公司业务发展高级总监Michele Dalla Libera先生(Michele先生)已于2025 年12月15日逝世。 ...

董事會對Michele先生的逝世表示深切哀悼，並向其家人致以誠摯慰問。同時，董事 會謹此對Michele先生多年來對本公司作出的寶貴貢獻、卓越領導以及堅定承諾表示 由衷的感謝。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因公佈全部或任何部 份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (於開曼群島註冊成立的有限公司) (股份代號：950) MICHELE DALLA LIBERA 離世 李氏大藥廠控股有限公司(「本公司」)董事會(「董事會」)沉痛宣佈，本公司業務發 展高級總監Michele Dalla Libera先生(「Michele先生」)已於二零二五年十二月十 五日逝世。 Michele先生在本公司的成長與發展過程中發揮了關鍵作用，尤其是在本公司於2002 年上市後的數年間。他與創始人緊密合作，引領本公司度過初創階段。他主導了從 義大利及其他歐洲國家引進藥品的工作，為本公司建立了核心產品組合，奠定了堅 ...

Core Viewpoint - The acquisition of Alexza Pharmaceuticals' assets, including the Staccato One Breath Technology platform, represents a significant strategic move for the company, enhancing its capabilities in aerosol drug delivery and expanding its inhalation product pipeline, aligning with its global expansion strategy [1][2]. Group 1: Acquisition Details - The company has established a wholly-owned subsidiary, Nova Pneuma Inc., to facilitate the acquisition of Alexza's assets, which include intellectual property, platform technology, trademarks, product pipelines, equipment, and GMP facility usage rights [1]. - The acquisition is expected to be completed by the end of 2025, pending specific closing conditions [1]. Group 2: Strategic Benefits - The acquisition of the Staccato OBT platform technology is a crucial step in the company's strategic expansion, providing full ownership of a mature and reliable technology platform validated by approved products and ongoing clinical development projects [2]. - This strategic move not only enhances the company's drug delivery capabilities but also lays the foundation for future innovations in inhalation therapies [2]. - The company will save costs by eliminating future royalty payments to Alexza, thereby optimizing the overall economic benefits of the transaction [2]. Group 3: Product Pipeline and Collaborations - The acquisition includes rights and obligations under existing global licensing and manufacturing supply agreements with UCB, a significant player in the epilepsy treatment field [3]. - UCB retains global development and commercialization rights for Staccato alprazolam, which is currently in Phase III clinical trials, further validating the clinical maturity and commercial potential of the Staccato OBT technology platform [3]. - The company is advancing clinical development for drugs targeting breakthrough pain related to cancer using the Staccato technology platform and has begun commercializing Adasuve in Greater China for acute agitation in adults with schizophrenia or bipolar I disorder [2][3].

Core Viewpoint - The acquisition of Alexza Pharmaceuticals, Inc.'s assets by Lee's Pharmaceutical Holdings Limited through its wholly-owned subsidiary Nova Pneuma Inc. represents a strategic move to enhance the company's capabilities in aerosol drug delivery and expand its inhalation product pipeline, aligning with its global expansion strategy [1][2]. Group 1: Acquisition Details - The acquisition grants the company full ownership of the Staccato® One Breath Technology® platform, including intellectual property, trademarks, product pipeline, and GMP facility usage rights [1]. - The transaction is expected to be completed by the end of 2025, pending specific closing conditions [1]. Group 2: Strategic Benefits - The acquisition is a significant step in the company's strategic expansion, enhancing its drug delivery capabilities and laying the foundation for future innovations in inhalation therapy [2]. - The company will save costs by eliminating future royalty payments to Alexza, optimizing the overall economic benefits of the transaction [2]. - The acquisition includes central nervous system pipeline assets for Parkinson's disease and cyclic vomiting syndrome, both in Phase II clinical trials, creating new commercial opportunities [2]. Group 3: Collaboration and Market Potential - The company also acquires rights and obligations under existing global licensing and manufacturing agreements with UCB, a prominent biopharmaceutical company in epilepsy treatment [3]. - UCB retains global development and commercialization rights for Staccato® alprazolam, which is currently in Phase III clinical trials, further validating the clinical maturity and commercial potential of the Staccato® OBT® technology platform [3]. - The founder of the company emphasized that this acquisition represents a transformative initiative, enhancing the product pipeline and research capabilities in inhalation treatments while creating new revenue sources through strategic collaboration with UCB [3].

Core Viewpoint - The acquisition of Alexza Pharmaceuticals, Inc. by Lee's Pharmaceutical Holdings Limited through its wholly-owned subsidiary Nova Pneuma Inc. represents a strategic move to enhance the company's capabilities in aerosol drug delivery and expand its inhalation product pipeline, aligning with its global expansion strategy [2][3]. Group 1: Acquisition Details - The acquisition grants the company full ownership of the Staccato® One Breath Technology® platform, including intellectual property, trademarks, product pipeline, and GMP facility usage rights [2]. - The transaction is expected to be completed by the end of 2025, subject to specific closing conditions [2]. Group 2: Strategic Benefits - The acquisition is a significant step in the company's strategic expansion, enhancing its drug delivery capabilities and laying the foundation for future innovations in inhalation therapies [3]. - The company will save costs by eliminating future royalty payments to Alexza, optimizing overall transaction economics [3]. - The acquisition includes two central nervous system pipeline assets in Phase II clinical trials for Parkinson's disease and cyclic vomiting syndrome, creating new commercial opportunities [3]. Group 3: Collaboration and Market Potential - The company also acquires rights and obligations under existing global licensing and manufacturing supply agreements with UCB, a prominent biopharmaceutical company in epilepsy treatment [4]. - UCB retains global development and commercialization rights for Staccato® alprazolam, which is currently in Phase III clinical trials, further validating the clinical maturity and commercial potential of the Staccato® OBT® technology platform [4]. - The founder of the company emphasized that this acquisition represents a transformative initiative, enhancing the product pipeline and research capabilities in inhalation treatments for central nervous system and neurodegenerative diseases, while creating new revenue streams through strategic collaboration with UCB [4].

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950.HK) has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals, Inc. for a total consideration of $15 million (approximately HKD 117 million) [1][2] Group 1: Acquisition Details - The assets being acquired include nearly all assets associated with Alexza's business, primarily the Staccato® platform technology, which is an inhalation drug delivery technology, along with related intellectual property, product pipeline, inventory, and contractual rights [2] - Key products involved in the acquisition include the approved Adasuve® and the late-stage development Staccato® alprazolam (for epilepsy), as well as other early-stage pipeline products [2] Group 2: Strategic Implications - The acquisition allows Lee's Pharmaceutical to fully own the clinically validated Staccato® inhalation drug delivery technology platform, which complements its existing product pipeline, including the developing Staccato®-based drugs [2] - The company will benefit from multiple research and development projects, including those targeting central nervous system diseases, and will avoid future royalty payments [2] - Through a licensing agreement with UCB, the company may receive up to $60.5 million in milestone payments, tiered royalties on sales, and manufacturing revenue in the future [2]